<DOC>
	<DOC>NCT01657799</DOC>
	<brief_summary>The primary objective of this study is to evaluate the Overall Survival, Best Tumor Response Rate, Time to Intracranial Progression (radiographic), Time to Clinical Brain Metastasis Progression, safety, and tolerability of veliparib and Whole Brain Radiation Therapy in subjects with brain metastases from Non Small Cell Lung Cancer</brief_summary>
	<brief_title>A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Subject must be greater than or equal to 18 years of age Subject must have cytologically or histologically confirmed nonsmall cell lung cancer Subject must have brain metastases demonstrated on a MRI brain scan Subject must be eligible for WBRT Subject is diagnosed with brain metastases greater than 28 days prior to treatment Subject received any prior form of cranial radiation and/or neurosurgery for their brain metastases Subject's last dose of anticancer therapy or investigational therapy was less than or equal to 7 days prior to treatment Subject has a Karnofsky Performance Score of less than 70 Subject has significant dyspnea requiring supplemental oxygen therapy Subject has liver metastases (restaging is not required for known liver metastases) Subject has more than 2 sites (organ systems) of metastases from nonsmall cell lung cancer with the exception of intracranial sites of metastases from nonsmall cell lung cancer, thoracic sites of metastases from nonsmall cell lung cancer and bone metastases Subject has leptomeningeal metastases or subarachnoid spread of tumor Subject has unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anticancer treatment Subject has a known seizure disorder that is uncontrolled, or has seizures occurring greater than or equal to 3 times a week over the past month. Subjects presenting with symptoms of seizures from the brain metastases are eligible; however he/she should receive adequate antiseizure medication prior to study treatment Subject is pregnant or lactating Subject has previously been treated with a poly(ADPribose)polymerase inhibitor as an investigational agent Subject has clinically significant and uncontrolled major medical condition(s) Subject has a history of another active cancer within the past 5 years except: cervical cancer in situ, in situ carcinoma of the bladder, basal or squamous cell carcinoma of the skin or other cancer in situ that is considered cured</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>